Krystal Biotech Doses First Patient in Phase 1/2 trial of KB103 Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), announced on 5/11/18 that the first patient has been dosed in the Phase 1/2, first in-human trial of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB).